GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Blueberries Medical BBM.CN · CAD

Health Care · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.01

—

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Blueberries Medical

Its shares trade on Canadian Securities Exchange under the ticker BBM.CN. It has been listed since 9 April 2014. In the fiscal year to 31 December 2025, it reported revenue of C$312,285 and a net loss of C$1.7m. At that date it held total assets of C$679,623 and shareholders' equity of C$321,171.

Blueberries Medical Corp. is engaged in the production and distribution of psychoactive and non-psychoactive cannabis by-products. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-04-09. The firm is engaged in the growth, cultivation, and development of medicinal cannabis and related products with operations in Colombia. The firm is focused on processing and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. The company is developing and commercializing a range of cannabis-derived ingredients, including high and low tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. The Company’s subsidiaries include Blueberries Research Corporation (BRC), Blueberries SAS (BBSAS), Centro De Desarrollo e Investigacion (CDIBBSAS), BBV Labs Inc. (BBV Labs.) and SATIN S.A.S. (SATIN). Blueberries SAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
9 Apr 2014

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Engaged in production and distribution of psychoactive and non-psychoactive cannabis by-products
  • Headquartered in Toronto, Ontario with operations in Colombia
  • Developing and commercializing cannabis-derived ingredients including THC, CBD, and other cannabinoids

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market position provided
  • No information on regulatory compliance beyond being a licensed producer in Colombia

Opportunities

  • Expansion of operations in Colombia through subsidiaries like Blueberries SAS
  • Growth potential in medicinal cannabis market for oil extracts and medical flowers
  • Development of new cannabis-derived ingredients for commercialization

Threats

  • Regulatory challenges in the cannabis industry
  • Dependence on cannabis market which may face legal or market volatility
  • Competition in the pharmaceutical sector for cannabis-derived products

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.